Omaveloxolone ameliorates isoproterenol-induced pathological cardiac hypertrophy in mice

References

• Bakhshi H, Michelhaugh SA, Bruce SA, et al. Association between proteomic biomarkers and myocardial fibrosis measured by MRI: the multi-ethnic study of atherosclerosis. EBioMedicine. 2023;90:104490. doi: 10.1016/j.ebiom.2023.104490.
   PubMed Web of Science ®Google Scholar
• Jia R, Zhang X, Xu Y, et al. Effect of sacubitril/valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: a real-world 12-week study. Eur J Pharmacol. 2022;928:175053. doi: 10.1016/j.ejphar.2022.175053.
   PubMed Web of Science ®Google Scholar
• Qian K, Tang J, Ling Y-J, et al. Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure. EBioMedicine. 2023;98:104863. doi: 10.1016/j.ebiom.2023.104863.
   PubMed Web of Science ®Google Scholar
• Kresoja K-P, Unterhuber M, Wachter R, et al. Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials. EBioMedicine. 2023;96:104795. doi: 10.1016/j.ebiom.2023.104795.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15(7):387–407. doi: 10.1038/s41569-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128(1):191–227. doi: 10.1016/j.pharmthera.2010.04.005.
   PubMed Web of Science ®Google Scholar
• Martinez-Quintana E, Estupinan-Leon H, et al. Quality of life in congenital heart disease patients according to their anatomical and physiological classification. " Congenit Heart Dis. 2023;18(2):197–206. doi: 10.32604/CHD.2021.013308
   Web of Science ®Google Scholar
• Yin A, Yuan R, Xiao Q, et al. Exercise-derived peptide protects against pathological cardiac remodeling. EBioMedicine. 2022;82:104164. doi: 10.1016/j.ebiom.2022.104164.
   PubMed Web of Science ®Google Scholar
• Park JS, Seo GH, et al. Factors affecting the genetic diagnostic rate in congenital heart disease. Congenit Heart Dis. 2022;17(6):653–673. doi: 10.32604/chd.2022.021580.
   Web of Science ®Google Scholar
• Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245–262. doi: 10.1016/j.yjmcc.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Wilson C, Zi M, Smith M, et al. Atrioventricular node dysfunction in pressure overload-induced heart failure-Involvement of the immune system and transcriptomic remodelling. Front Pharmacol. 2023;14:1083910. doi: 10.3389/fphar.2023.1083910.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao R, Wu C, et al. Activation of the sirtuin silent information regulator 1 pathway inhibits pathological myocardial remodeling. Front Pharmacol. 2023;14:1111320. doi: 10.3389/fphar.2023.1111320.
   PubMed Web of Science ®Google Scholar
• Zhen C, Wu X, Zhang J, et al. Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy. Front Pharmacol. 2023;14:1127123. doi: 10.3389/fphar.2023.1127123.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Qi G, Lu W, et al. Omaveloxolone inhibits IL-1beta-induced chondrocyte apoptosis through the Nrf2/ARE and NF-kappaB signalling pathways in vitro and attenuates osteoarthritis in vivo. Front Pharmacol. 2022;13:952950. doi: 10.3389/fphar.2022.952950.
   PubMed Web of Science ®Google Scholar
• Zhan J-Y, Zhang Y, Zhong X, et al. Liqi huoxue dripping pill protects against myocardial ischemia-reperfusion injury via the PI3K/akt/GSK-3 beta signaling pathway in rats. Tradit Med Res. 2023;8(4):21. doi: 10.53388/TMR20220903001.
   Web of Science ®Google Scholar
• Hu L, Cao Y, Chen H, et al. The novel Nrf2 activator omaveloxolone regulates microglia phenotype and ameliorates secondary brain injury after intracerebral hemorrhage in mice. Oxid Med Cell Longev. 2022;2022:4564471–4564418. doi: 10.1155/2022/4564471.
   PubMed Web of Science ®Google Scholar
• Jian W, Ma H, Wang D, et al. Omaveloxolone attenuates the sepsis-induced cardiomyopathy via activating the nuclear factor erythroid 2-related factor 2. Int Immunopharmacol. 2022;111:109067. doi: 10.1016/j.intimp.2022.109067.
   PubMed Web of Science ®Google Scholar
• Yang M-J, Han X-Y, Qiao O, et al. Effect of salvianolic acid B-loaded mesoporous silica nanoparticles on myocardial ischemia-reperfusion injury. Tradit Med Res. 2023;8(8):45. doi: 10.53388/TMR20230117001.
   Web of Science ®Google Scholar
• Yang Y, Xu C, Tang S, et al. Interleukin-9 aggravates isoproterenol-induced heart failure by activating signal transducer and activator of transcription 3 signalling. Can J Cardiol. 2020;36(11):1770–1781. doi: 10.1016/j.cjca.2020.01.011.
   PubMed Web of Science ®Google Scholar
• Yu S, Qian H, Tian D, et al. Linggui zhugan decoction activates the SIRT1-AMPK-PGC1alpha signaling pathway to improve mitochondrial and oxidative damage in rats with chronic heart failure caused by myocardial infarction. Front Pharmacol. 2023;14:1074837. doi: 10.3389/fphar.2023.1074837.
   PubMed Web of Science ®Google Scholar
• Zhou J-C, Jin C-C, Wei X-L, et al. Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy. Front Pharmacol. 2023;14:1118017. doi: 10.3389/fphar.2023.1118017.
   PubMed Web of Science ®Google Scholar
• Altieri DI, Etzion Y, Anderson HD. Cannabinoid receptor agonist attenuates angiotensin II-induced enlargement and mitochondrial dysfunction in rat atrial cardiomyocytes. Front Pharmacol. 2023;14:1142583.,. doi: 10.3389/fphar.2023.1142583.
   PubMed Web of Science ®Google Scholar
• Bjune MS, Lawrence-Archer L, Laupsa-Borge J, et al. Metabolic role of the hepatic valine/3-hydroxyisobutyrate (3-HIB) pathway in fatty liver disease. EBioMedicine. 2023;91:104569. doi: 10.1016/j.ebiom.2023.104569.
   PubMed Web of Science ®Google Scholar
• Wang J, Cai E, An X, et al. Ginaton reduces M1-polarized macrophages in hypertensive cardiac remodeling via NF-κB signaling. Front Pharmacol. 2023;14:1104871. doi: 10.3389/fphar.2023.1104871.
   PubMed Web of Science ®Google Scholar
• Hong X, Jian Y, Ding S, et al. Kir4.1 channel activation in NG2 glia contributes to remyelination in ischemic stroke. EBioMedicine. 2023;87:104406. doi: 10.1016/j.ebiom.2022.104406.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIe study). Ann Neurol. 2021;89(2):212–225. doi: 10.1002/ana.25934.
   PubMed Web of Science ®Google Scholar
• Shanmugam G, Challa AK, Litovsky SH, et al. Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice. Redox Biol. 2019;27:101212. doi: 10.1016/j.redox.2019.101212.
   PubMed Web of Science ®Google Scholar
• Senoner T, Dichtl W. Oxidative stress in cardiovascular diseases: still a therapeutic target? Nutrients. 2019;11(9):2090. doi: 10.3390/nu11092090.
   PubMed Web of Science ®Google Scholar
• Wan R, Srikaram P, Guntupalli V, et al. Cellular senescence in asthma: from pathogenesis to therapeutic challenges. EBioMedicine. 2023;94:104717. doi: 10.1016/j.ebiom.2023.104717.
   PubMed Web of Science ®Google Scholar
• Crnko S, Printezi MI, Zwetsloot P-PM, et al. The circadian clock remains intact, but with dampened hormonal output in heart failure. EBioMedicine. 2023;91:104556. doi: 10.1016/j.ebiom.2023.104556.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tan Y, Huang C, et al. Redox signaling in drug-tolerant persister cells as an emerging therapeutic target. EBioMedicine. 2023;89:104483. doi: 10.1016/j.ebiom.2023.104483.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Zong X, Yang Q, et al. Interleukin-34-NF-kappaB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization. EBioMedicine. 2023;95:104744. doi: 10.1016/j.ebiom.2023.104744.
   PubMed Web of Science ®Google Scholar
• Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180–183. doi: 10.1016/j.redox.2015.01.002.
   PubMed Web of Science ®Google Scholar
• Wei JJ, Du JL. Mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure. Cardiovasc Innov Appl. 2023;8(1). doi: 10.15212/CVIA.2023.0028.
   Web of Science ®Google Scholar
• Yang Y, Xia Z, Xu C, et al. Ciprofol attenuates the isoproterenol-induced oxidative damage, inflammatory response and cardiomyocyte apoptosis. Front Pharmacol. 2022;13:1037151. doi: 10.3389/fphar.2022.1037151.
   PubMed Web of Science ®Google Scholar
• Mu L, Ye Z, Hu J, et al. PPM1K-regulated impaired catabolism of branched-chain amino acids orchestrates polycystic ovary syndrome. EBioMedicine. 2023;89:104492. doi: 10.1016/j.ebiom.2023.104492.
   PubMed Web of Science ®Google Scholar
• Vaikunthanathan T, Landmann E, Correa DM, et al. Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease. EBioMedicine. 2023;95:104778. doi: 10.1016/j.ebiom.2023.104778.
   PubMed Web of Science ®Google Scholar
• Daiber A, Steven S, Euler G, et al. Vascular and cardiac oxidative stress and inflammation as targets for cardioprotection. Curr Pharm Des. 2021;27(18):2112–2130. doi: 10.2174/1381612827666210125155821.
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu T, He S, et al. Ursolic acid reduces oxidative stress injury to ameliorate experimental autoimmune myocarditis by activating Nrf2/HO-1 signaling pathway. Front Pharmacol. 2023;14:1189372. doi: 10.3389/fphar.2023.1189372.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen Q, Zhao J, et al. A four-compound remedy AGILe protected H9c2 cardiomyocytes against oxygen glucose deprivation via targeting the TNF-α/NF-κB pathway: implications for the therapy of myocardial infarction. Front Pharmacol. 2023;14:1050970. doi: 10.3389/fphar.2023.1050970.
   PubMed Web of Science ®Google Scholar
• Chang C, Cai RP. Uncovering the genetic link between acute myocardial infarction and ulcerative colitis Co-Morbidity through a systems biology approach. Cardiovasc Innov Appl. 2023;8(1). doi: 10.15212/CVIA.2023.0034.
   Web of Science ®Google Scholar
• Zhao L, Cheng G, Jin R, et al. Deletion of interleukin-6 attenuates pressure Overload-Induced left ventricular hypertrophy and dysfunction. Circ Res. 2016;118(12):1918–1929. doi: 10.1161/CIRCRESAHA.116.308688.
   PubMed Web of Science ®Google Scholar
• Bai Y, Wu H, Zheng L, et al. Mechanisms of yajieshaba in the treatment of liver fibrosis through the Keap1-Nrf2 signaling pathway. Front Pharmacol. 2023;14:1124015. doi: 10.3389/fphar.2023.1124015.
   PubMed Web of Science ®Google Scholar
• Chen T, Hu Y, Lu L, et al. Myricetin attenuates hypoxic-ischemic brain damage in neonatal rats via NRF2 signaling pathway. Front Pharmacol. 2023;14:1134464. doi: 10.3389/fphar.2023.1134464.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tang B, Li H, et al. A small-molecule inhibitor of Keap1-Nrf2 interaction attenuates sepsis by selectively augmenting the antibacterial defence of macrophages at infection sites. EBioMedicine. 2023;90:104480. doi: 10.1016/j.ebiom.2023.104480.
   PubMed Web of Science ®Google Scholar
• Lou L, Wang M, He J, et al. Urolithin A (UA) attenuates ferroptosis in LPS-induced acute lung injury in mice by upregulating Keap1-Nrf2/HO-1 signaling pathway. Front Pharmacol. 2023;14:1067402. doi: 10.3389/fphar.2023.1067402.
   PubMed Web of Science ®Google Scholar
• Zhao C, Xiao C, Feng S, et al. Artemisitene alters LPS-Induced oxidative stress, inflammation and ferroptosis in liver through Nrf2/HO-1 and NF-kB pathway. Front Pharmacol. 2023;14:1177542. doi: 10.3389/fphar.2023.1177542.
   PubMed Web of Science ®Google Scholar
• Bellezza I, Giambanco I, Minelli A, et al. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865(5):721–733. doi: 10.1016/j.bbamcr.2018.02.010.
   PubMed Web of Science ®Google Scholar
• Chen QM, Maltagliati AJ. Nrf2 at the heart of oxidative stress and cardiac protection. Physiol Genomics. 2018;50(2):77–97. doi: 10.1152/physiolgenomics.00041.2017.
   PubMed Web of Science ®Google Scholar
• Liu J, Li X, Ding L, et al. GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress. Int Immunopharmacol. 2023;117:109957. doi: 10.1016/j.intimp.2023.109957.
   PubMed Web of Science ®Google Scholar
• Park WY, Kim GB, Lee SY, et al. Long-Term outcome and risk factor analysis of surgical pulmonary valve replacement in congenital heart disease. Congenit Heart Dis. 2022;17(3):335–350. doi: 10.32604/chd.2022.018666.
   Web of Science ®Google Scholar
• Aquila I, Cianflone E, Scalise M, et al. c-kit haploinsufficiency impairs adult cardiac stem cell growth, myogenicity and myocardial regeneration. Cell Death Dis. 2019;10(6):436. doi: 10.1038/s41419-019-1655-5.
   PubMedGoogle Scholar
• Salerno N, Scalise M, Marino F, et al. A mouse model of dilated cardiomyopathy produced by isoproterenol acute exposure followed by 5-Fluorouracil administration. J Cardiovasc Dev Dis. 2023;10(6):225. doi: 10.3390/jcdd10060225.
   PubMed Web of Science ®Google Scholar
• Ehler E, Moore-Morris T, et al. Isolation and culture of neonatal mouse cardiomyocytes. J Vis. 2013;(79):50154.
   Google Scholar
• Wang X, Li W, Zhang Y, et al. Calycosin as a novel PI3K activator reduces inflammation and fibrosis in heart failure through AKT-IKK/STAT3 axis. Front Pharmacol. 2022;13:828061. doi: 10.3389/fphar.2022.828061.
   PubMed Web of Science ®Google Scholar